• Helix BioPharma Corp., of Aurora, Ontario, appointed Jack M. Kay chairman and appointed Kazimierz Roszkowski-Sliz European medical director.

• Horizon Discovery Ltd., of Cambridge, UK, appointed Simon Cook to its board. It also appointed Eric Rhodes chief technical officer of gene targeting.

• ImmunoGen Inc., of Waltham, Mass., added Kristine Peterson and Dean Mitchell to its board.

• InterMune Inc., of Brisbane, Calif., appointed Jonathan A. Leff executive vice president of R&D.

• Jazz Pharmaceuticals plc, of Dublin, Ireland, appointed Suzanne Sawochka Hooper general counsel and an executive officer, effective in March; named Fintan Keegan senior vice president of technical operations; and added Eunan Maguire senior vice president of strategy and corporate development.

• Ligand Pharmaceuticals Inc., of San Diego, appointed Nishan de Silva vice president of corporate development.

• Lycera Corp., of Ann Arbor, Mich., appointed Steven Gillis chairman and added Michael Steinmetz to its board.

• MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed W. James O'Shea to its board.